Inovio reports interim Phase I data for HBV candidate

By Sandi Wong | Mar 23, 2018 | 5:24 PM GMT

Inovio Pharmaceuticals Inc. (NASDAQ:INO) reported interim data from a Phase I trial showing that HBV candidate INO-1800